Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.
Results from a Phase 1 clinical trial of mirvetuximab soravtansine (IMGN853) as a treatment for chemotherapy-resistant ovarian cancer and other malignancies have propelled the therapy into a Phase 3 trial. ... Read more
Syros Pharmaceuticals’ investigational compound SY-1365 showed potent anticancer activity in cell and animal models of ovarian cancer, giving the company momentum to move toward the Phase 1 trial it plans later ... Read more
Most women with epithelial ovarian cancer have circulating tumor cells, and among those who recently received their cancer diagnosis, the more such cells they had, the shorter their survival times, ... Read more
Long-term, progression-free survival in women with ovarian cancer treated with Lynparza (olaparib) is likely linked to deficient DNA repair mechanisms, particularly those caused by mutations in the BRCA genes. In ... Read more
A gene previously thought to contribute to ovarian cancer by disrupting the well-known BRCA genes, is driving cancer growth independently of the other factors, new research shows. The discovery is ... Read more
A lucky circumstance led scientists, working in mice, to discover that nanoparticle-delivered siRNA blockers of a molecule found in ovarian cancer can dramatically improve response to chemotherapy. The siRNA molecules ... Read more